Pathology: la/mBC - HER2 positive - 1st Line (L1);
la/mBC - HER2 positive - 1st Line (L1) | |||||
PERTAIN, 2018 | CLEOPATRA, 2012 | PUFFIN, 2020 | SYSUCC-002, 2022 | ||
pertuzumab plus trastuzumab plus docetaxel | 2 | T1 | T1 | ||
trastuzumab plus endocrine therapy | 1 | T1 | |||
pertuzumab plus trastuzumab | 1 | T1 | |||
trastuzumab plus chemotherapy | 0 | T0 | |||
trastuzumab | 0 | T0 | |||
trastuzumab plus docetaxel | 0 | T0 | T0 |